Chronic myeloid leukaemia

Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm driven by BCR::ABL1. This entry covers chronic phase, TKIs, and monitoring.

Overview

Chronic Myeloid Leukaemia (CML) is a clonal myeloproliferative neoplasm (MPN) characterised by the uncontrolled proliferation of relatively mature myeloid cells (granulocytes and their precursors) in the bone marrow, peripheral blood, and spleen. It accounts for approximately 15% of all adult leukaemias in Western countries, with an annual incidence of roughly 1 to 2 cases per 100,000 population.

The hallmark of CML is the Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11.2). This translocation creates the BCR-ABL1 fusion gene, which encodes a constitutively active tyrosine kinase. This oncoprotein drives the malignant phenotype by activating downstream signalling pathways (PI3K/AKT, RAS/MAPK, JAK/STAT) that promote proliferation, inhibit apoptosis, and confer genomic instability.

Historically, CML was a fatal disease with a median survival of 3–5 years. The advent of Tyrosine Kinase Inhibitors (TKIs)—starting with imatinib in 2001—has revolutionised management, transforming CML into a chronic, manageable condition for the vast majority of patients. Today, patients achieving a deep molecular response (DMR) on TKI therapy have a life expectancy approaching that of the general population, and a subset of patients may even safely discontinue therapy (Treatment-Free Remission, TFR).

Aetiology and Risk Factors

The exact trigger for the t(9;22) translocation remains unknown in most cases. It is an acquired somatic mutation, not inherited.

Risk Factor	Association Strength	Notes
Ionising Radiation	Established	High-dose exposure (atomic bomb survivors, radiotherapy for ankylosing spondylitis) increases risk. Latency period 5–20 years. Low-dose diagnostic radiation (X-rays, CT) has not been conclusively linked.
Age	Strong	Median age at diagnosis: 55–65 years. Rare in children (< 5% of cases) and young adults. Incidence rises sharply after age 40.
Sex	Moderate	Male-to-female ratio approx. 1.3:1 to 1.5:1.
Chemical Exposures	Weak/Inconclusive	Benzene exposure is linked to AML; evidence for CML is inconsistent. Agricultural chemicals/pesticides studied but no definitive causal link established.
Genetic Predisposition	Very Low	No strong familial syndrome. First-degree relatives have a slightly elevated relative risk (approx. 2-3x), but absolute risk remains extremely low.
Viruses/Infection	None Proven	Unlike HTLV-1 and ATLL, no viral aetiology identified for CML.

For the overwhelming majority of patients, no identifiable risk factor exists. CML arises from a stochastic (random) error in DNA repair during haematopoietic stem cell division.

Pathophysiology: The BCR-ABL1 Oncogene

Understanding the molecular driver is essential to understanding the disease presentation and treatment.

The Translocation: Breakpoints on chromosome 9 (ABL1 gene) and chromosome 22 (BCR gene) fuse.
The Fusion Protein: The size of the BCR breakpoint determines the protein size:

p210 BCR-ABL1 (e13a2 / e14a2 transcripts): Classic CML (95% of cases).
p190 BCR-ABL1 (e1a2 transcript): Associated with Ph+ Acute Lymphoblastic Leukaemia (ALL), but seen in ~5% of CML (often presents with higher platelet counts, lower leukocyte counts).
p230 BCR-ABL1 (e19a2 transcript): Rare, associated with neutrophilic CML variant, indolent course.

Mechanism of Action: The fusion protein possesses constitutive tyrosine kinase activity (unlike normal c-ABL, which is tightly regulated). This leads to:

Genomic Instability: Impaired DNA repair (downregulation of DNA-PK, BRCA1).
Altered Adhesion: Dysregulation of integrin signalling → premature release of progenitors from marrow into blood (explains high circulating blasts/progenitors).
Cytokine Independence: Growth factor-independent survival (via PI3K/AKT, JAK/STAT).
Inhibition of Apoptosis: Upregulation of BCL-2, BCL-XL.

Disease Phases (Natural History)

Without effective therapy, CML progresses through three distinct phases. Accurate phase assignment at diagnosis is critical for risk stratification and treatment selection.

1. Chronic Phase (CP-CML)

Prevalence: ~85–90% of patients at diagnosis.
Definition: Blasts < 10% in peripheral blood (PB) and bone marrow (BM); Basophils < 20%; Platelets ≥ 100 × 10⁹/L; No extramedullary proliferation (except spleen/liver).
Clinical Course: Relatively indolent. Symptoms often mild or absent. If untreated, median duration 3–5 years before progression.

2. Accelerated Phase (AP-CML)

Prevalence: ~10–15% at diagnosis (less common now due to earlier detection).
Definitions vary slightly (WHO vs. MD Anderson vs. International Prognostic Score), but common criteria include:
Blasts 10–19% in PB or BM.
Basophils ≥ 20% of white cell count.
Platelets < 100 × 10⁹/L (unrelated to therapy).
Increasing spleen size/unresponsive to therapy.
Additional Cytogenetic Abnormalities (ACA): e.g., +8, i(17q), +19, second Ph chromosome.
Significance: Intermediate prognosis. Higher risk of progression to Blast Phase. Requires more potent TKIs (2nd/3rd generation) upfront.

3. Blast Phase (BP-CML / Blast Crisis)

Prevalence: Rare at diagnosis (< 5%) due to screening; occurs in untreated/poorly controlled CP/AP.
Definition: Blasts ≥ 20% in PB or BM; OR Extramedullary proliferation of blasts (e.g., skin, lymph nodes, bone); OR Large foci of blasts in BM biopsy.
Lineage:
Myeloid (~60-70%): Resembles AML. Express MPO, CD13, CD33, CD117.
Lymphoid (~20-30%): Resembles ALL. Express CD19, CD10, CD22, TdT. Crucial distinction: Lymphoid BP responds better to ALL-type chemo + TKI and may be eligible for Allogeneic Stem Cell Transplant (allo-SCT) in CR1.
Mixed/Undifferentiated (~10%).
Prognosis: Poor. Treated as acute leukaemia (induction chemo + potent TKI) with urgent referral for allo-SCT.

How Does It Look: Clinical Findings, Laboratory & Imaging Hallmarks

This section details the phenotypic manifestation of the disease—what the clinician sees on examination, what the automated analyser flags, and what the morphologist visualises under the microscope.

1. Physical Examination Findings

Finding	Frequency (CP)	Description & Clinical Nuance
Splenomegaly	90–95%	The hallmark physical sign. Ranges from palpable tip (2–3 cm below costal margin) to massive (crossing midline, reaching pelvis). Caused by extramedullary haematopoiesis and leukemic infiltration. Massive splenomegaly (> 20 cm) suggests AP/BP or high tumour burden.
Hepatomegaly	20–40%	Usually mild (2–4 cm below costal margin). Massive hepatomegaly is rare in CP, more common in AP/BP.
Lymphadenopathy	< 5% (CP)	Uncommon in CP. Presence of significant cervical, axillary, or inguinal lymphadenopathy (> 2 cm) raises strong suspicion for Accelerated or Blast Phase (especially lymphoid BP) or concurrent infection.
Skin Changes	Rare	Leukaemia cutis: Firm, non-tender nodules/plaques (infiltration by neoplastic cells) → Blast Phase. <br> Sweet’s Syndrome (Febrile Neutrophilic Dermatosis): Painful erythematous plaques, fever, neutrophilia. Paraneoplastic, can occur in CP but warrants BP exclusion.
Gouty Tophi	Rare	Due to hyperuricaemia from high cell turnover. Usually only in very high WBC counts (> 300 × 10⁹/L) or after cytotoxic therapy initiation (TLS risk).
Pallor	Variable	Sign of anaemia (Hb < 100 g/L). Common at diagnosis due to marrow displacement and cytokine suppression of erythropoiesis.

2. Peripheral Blood (PB) Morphology – “The Blood Film”

The peripheral blood film in CML is often diagnostic even before genetic confirmation. It resembles a “bone marrow aspirate spilled into the blood” due to the loss of marrow retention signals.

Cell Population	Typical Appearance in CP-CML	Diagnostic Significance
Neutrophils (Mature)	Markedly increased (Leukocytosis 20–500 × 10⁹/L). Normal segmentation, toxic granulation rare (unless infection).	Maturation is preserved (Myelocytes → Metamyelocytes → Bands → Segs). This “full spectrum” differentiates CML from Leukemoid Reaction (where mature forms dominate) and AML (where maturation arrest occurs).
Left Shift (Precursors)	Myelocytes, Metamyelocytes, Promyelocytes commonly seen. Blasts usually < 5% (CP).	The Myelocyte:Blast ratio is high. Promyelocytes may have Auer rods (rare, suggests AP/BP).
Basophilia	Present in > 90% of cases. Usually 2–10%, can exceed 20% (AP criterion).	Highly specific for CML among MPNs. Basophils release histamine → pruritus, flushing, anaphylaxis risk.
Eosinophilia	Common (5–20%).	Often parallels basophilia. Can cause tissue infiltration (heart, lung) if extreme.
Monocytosis	Variable. > 10% or > 1 × 10⁹/L suggests AP or CMML overlap.	Monocytosis > 10% of WBC is an AP criterion (WHO).
Platelets	Thrombocytosis (400–1000 × 10⁹/L) in ~25-50% of CP. <br> Thrombocytopenia (< 100 × 10⁹/L) = AP criterion (bad prognosis).	Large, granular platelets often seen (megakaryocyte fragmentation).
Red Cells	Normocytic, normochromic anaemia common. <br> Teardrop cells (dacrocytes) + Nucleated RBCs = “Leucoerythroblastic” picture → suggests marrow fibrosis/infiltration.	Leucoerythroblastic film suggests Myelofibrosis (can coexist with CML) or Blast Phase.

Morphology Pearl: Pseudo-Pelger-Huët anomaly (hyposegmented neutrophils, “bilobed” or “pince-nez” nuclei) can be seen in CML due to BCR-ABL1 effect on nuclear maturation. It is not** indicative of MDS in this context.

3. Bone Marrow (BM) Aspiration & Trephine Biopsy

Indication: Mandatory at diagnosis for phase confirmation, fibrosis assessment, and cytogenetics. Not routinely required for monitoring on TKI (replaced by PCR), but indicated for failure, progression, or pre-transplant.

Aspiration (Liquid Marrow)

Cellularity: Markedly hypercellular (90–100%), often “packed” (difficult to make films).
Myeloid:Erythroid (M:E) Ratio: Markedly increased (10:1 to 50:1; normal ~3:1).
Maturation: Ordered maturation (full spectrum) – key differentiator from AML.
Megakaryocytes: Increased number, often small, hypolobated (dwarf megakaryocytes), scattered singly or in small clusters. This is a classic CML feature.
Blasts: < 10% (CP). Count 200 cells minimum.
Fibrosis: Reticulin staining on clot section. Grade 1-2 common in CP; Grade 3-4 suggests AP/BP or primary myelofibrosis overlap.

Trephine Biopsy (Core) – Architecture

Overall Architecture: Diffuse, hypercellular myeloid proliferation. Fat spaces obliterated.
Megakaryocyte Distribution: Clustering is common. Small, monolobated forms predominate.
Fibrosis (Reticulin/Trichrome): Grade 0-1 (CP). Grade 2-3 (AP/BP). Collagen fibrosis (trichrome+) = advanced disease.
Osteosclerosis: New bone formation (Wormian bone) often seen in advanced phases.
Blast Clusters: Focal aggregates of blasts (> 5-10 cells) on biopsy may upstage to AP even if aspirate blast count is low (sampling error).

4. Cytogenetics & Molecular Diagnostics (The “Specs”)

Test	Target	Sensitivity	Turnaround	Role
Karyotyping (G-banding)	t(9;22), ACA, Clonal evolution	~5–10% (20 metaphases)	7–14 days	Gold standard for Phase Diagnosis. Detects ACA (AP criterion). Required at baseline.
FISH (Interphase)	BCR-ABL1 fusion (Dual fusion probe)	1–5% (200–500 nuclei)	24–48 hrs	Rapid diagnosis. Used if karyotype fails or for rapid AP/BP confirmation. Detects cryptic insertions.
RT-qPCR (Quantitative)	BCR-ABL1 transcript (e13a2/e14a2)	0.001% (MR4.5) / 0.0001% (MR5)	3–7 days	Gold standard for Monitoring. Results reported on International Scale (IS). Essential for TFR eligibility.
Mutation Analysis (NGS/Sanger)	ABL1 Kinase Domain (KD) mutations (T315I, Y253H, E255K, etc.)	~5–15% (Sanger) <br> < 1% (NGS)	1–3 weeks	Indicated for Treatment Failure / Suboptimal Response / Progression. Guides TKI switch.

Reporting Standard: BCR-ABL1 results must be reported on the International Scale (IS). Major Molecular Response (MMR / MR3): ≤ 0.1% IS. Deep Molecular Response (DMR): MR4 (≤ 0.01%), MR4.5 (≤ 0.0032%), MR5 (≤ 0.001%). Undetectable (U): Transcripts not detected with adequate control gene copies (≥ 10,000 ABL1 or GUSB copies).

Symptoms: Clinical Presentation in Detail

Symptoms in CML correlate poorly with white cell count but strongly with tumour burden (spleen size), cytokine release, and disease phase. Many patients (20–40%) are asymptomatic, diagnosed incidentally on a routine Full Blood Count (FBC).

1. Constitutional (“B”) Symptoms

Fatigue / Lethargy: Most common symptom (50–60%). Multifactorial: anaemia, cytokine-mediated (TNF-α, IL-6), sleep disruption from splenomegaly.
Night Sweats: Drenching, requiring clothing/bedding change. Caused by cytokine release (IL-1, TNF) and high metabolic turnover of leukemic mass. Red flag for progression if new/worsening on TKI.
Weight Loss: Unintentional > 10% body weight in 6 months. Anorexia + hypermetabolic state + early satiety.
Low-grade Fever: < 38°C, often diurnal. Exclude infection first. Persistent fever suggests progression or transformation.

Early Satiety: Very common (30–50%). Patient cannot eat a normal meal; feels full after few bites. Leads to weight loss and nutritional deficiency.
Left Upper Quadrant (LUQ) Pain / Discomfort: Dull, dragging sensation. Radiates to left shoulder (Kehr’s sign – diaphragmatic irritation) or back.
Incidental Finding: “My trousers feel tight” or “I feel a lump.”
Splenic Infarction: Sudden, severe LUQ pain + peritoneal signs + fever. Caused by vascular occlusion in massive spleen. Requires analgesia, hydration, rarely splenectomy.

3. Hyperviscosity / Leukostasis Symptoms (Medical Emergency)

Threshold: Usually WBC > 300–400 × 10⁹/L (higher threshold than AML due to deformability of mature neutrophils, but risk increases exponentially).
Neurological: Headache, confusion, dizziness, visual disturbances (retinal haemorrhages, papilloedema), stroke/TIA, coma.
Respiratory: Dyspnoea, hypoxia (pulmonary leukostasis).
Priapism: Painful prolonged erection (corpus cavernosum leukostasis). Urological emergency.
Management: Urgent Leukapheresis + Hydration + TKI initiation (Imatinib/Dasatinib) + Hydroxyurea bridge. Do not delay TKI start for leukapheresis if unavailable.

4. Cytokine / Mediator Release Symptoms

Pruritus (Itch): Classic CML symptom. Often worse after hot shower/bath (aquagenic pruritus). Caused by basophil histamine/protease release. May precede diagnosis by months. Responds rapidly to TKI.
Flushing: Episodic facial/upper body redness, warmth. Basophil-mediated.
Peptic Ulcer / GI Distress: High histamine → gastric acid hypersecretion. Increased risk of duodenal ulcers.
Gout / Uric Acid Nephrolithiasis: Purine turnover from high cell mass. Risk increases with cytoreductive therapy (Tumour Lysis Syndrome – TLS).

5. Haematological Complication Symptoms

Anaemia Symptoms: Dyspnoea on exertion, palpitations, angina (in CAD patients), worsened fatigue.
Thrombocytopenia (Platelets < 50 × 10⁹/L): Petechiae, ecchymoses, epistaxis, gum bleeding, menorrhagia. In CP, thrombocytopenia usually = AP or TKI toxicity (not disease).
Thrombocytosis (Platelets > 1000 × 10⁹/L): Erythromelalgia (burning pain, redness, heat in hands/feet – platelet microthrombi), arterial/venous thrombosis (stroke, MI, Budd-Chiari), paradoxical bleeding (acquired von Willebrand syndrome).
Infection: Despite high WBC, functional neutropenia can occur (impaired chemotaxis, adhesion). Risk increases in AP/BP or during TKI-induced myelosuppression.

6. Symptoms by Disease Phase

Symptom Cluster	Chronic Phase (CP)	Accelerated Phase (AP)	Blast Phase (BP)
General	Mild fatigue, incidental finding, pruritus, early satiety.	Worsening fatigue, new B-symptoms (fever, night sweats, weight loss), bone pain.	Severe B-symptoms, rapid deterioration, infection (neutropenia), bleeding.
Spleen	Stable or slowly progressive.	Rapidly increasing size, refractory to TKI, infarction pain.	Massive, often fixed/tender.
Blood Counts	High WBC, Plt normal/high.	Thrombocytopenia (<100k), rising blasts (10-19%), basophilia >20%, rising dose requirements.	Cytopenias (Anaemia, Thrombocytopenia, Neutropenia), Blasts ≥20%.
Specifics	Aquagenic pruritus, gout.	New cytogenetic abnormalities (ACA).	Extramedullary disease (skin, nodes, CNS, bone), leucostasis.

Clinical Pearl: Bone pain (especially sternal tenderness, long bone pain) is uncommon in CP. Its presence should prompt investigation for Blast Phase, Vitamin D deficiency, or TKI side effect** (dasatinib/ponatinib myalgia).

Diagnosis: Diagnostic Algorithm & Criteria

WHO 2022 / ICC 2022 Diagnostic Criteria for CP-CML

All major criteria required:

Peripheral Blood: Leukocytosis (≥ 10 × 10⁹/L) with left-shifted myeloid maturation (myelocytes, metamyelocytes), < 10% blasts, < 20% basophils, platelets ≥ 100 × 10⁹/L.
Bone Marrow: Hypercellularity, myeloid hyperplasia with ordered maturation, < 10% blasts, increased dysplastic megakaryocytes (small, hypolobated).
Genetics: Presence of BCR-ABL1 fusion (t(9;22) or variant) by karyotype, FISH, or RT-PCR.
Exclusion: No history of prior cytotoxic/chemotherapy for unrelated malignancy (therapy-related MPN exclusion).

Differential Diagnosis (The “Rule Out” List)

Condition	Key Differentiating Features
Leukemoid Reaction	WBC usually < 50 × 10⁹/L; No basophilia/eosinophilia; No splenomegaly (or mild); LAP Score High (CML = Low); Negative BCR-ABL1; Reactive cause evident (infection, steroids, stress).
Chronic Neutrophilic Leukaemia (CNL)	Mature neutrophils only (no left shift); CSF3R T618I mutation; No BCR-ABL1; No basophilia; Splenomegaly mild.
Atypical CML (aCML)	Dysgranulopoiesis prominent; No BCR-ABL1; Often SETBP1, ASXL1, TET2 mutations; Poor response to TKIs.
CML-like MPN (Ph-negative)	JAK2 V617F, CALR, MPL mutations (PV, ET, PMF); No BCR-ABL1.
Ph+ Acute Lymphoblastic Leukaemia (ALL)	Blasts ≥ 20% (lymphoid morphology/immunophenotype); Presents acutely; BCR-ABL1 usually p190.
Systemic Mastocytosis	Mast cell infiltration (skin, BM); KIT D816V; No BCR-ABL1; Tryptase elevated.

Risk Stratification at Diagnosis (Chronic Phase)

Before initiating TKI therapy, risk scores predict probability of achieving treatment milestones (MMR, DMR) and risk of progression. They do NOT dictate whether to treat (all CP-CML needs treatment), but which TKI to choose.

1. Sokal Score (Pre-TKI era, clinical/haematological)

$$ text{Score} = exp(0.0116 times (text{Age} – 43) + 0.0345 times (text{Spleen cm} – 7.5) + 0.188 times ((text{Plt}/700)^2 – 0.563) + 0.0887 times (log(text{WBC}) – 2.89)) $$

Low: < 0.8 | Intermediate: 0.8–1.2 | High: > 1.2

2. Hasford (Euro) Score (Adds eosinophils/basophils)

Incorporates: Age, Spleen, Platelets, WBC, % Eosinophils, % Basophils, % Blasts in PB.

Better discriminates Intermediate risk.

3. EUTOS Long-Term Survival (ELTS) Score (Current Standard for TKI Era)

Developed specifically for TKI-treated patients. Predicts CML-related death.

Variables: Age, Spleen size, Platelets, % Blasts in PB.
Groups: Low (0–1), Intermediate (2), High (≥ 3).
Utility: High-risk ELTS → Start 2nd/3rd Gen TKI (Nilotinib, Dasatinib, Bosutinib, Ponatinib). Low-risk → Imatinib or 2nd Gen acceptable.

Table: ELTS Risk Group & 10-Year CML Survival Probability

Risk Group	Score	10-yr CML Survival	Recommended 1st Line TKI Strategy
Low	0 – 1	> 95%	Imatinib or 2nd Gen (Patient choice/cost/comorbidity)
Intermediate	2	~90%	Prefer 2nd Gen (Faster/Deeper responses)
High	≥ 3	~75–80%	Mandate 2nd/3rd Gen (Bosutinib, Ponatinib if T315I suspected)

Treatment: The TKI Era & Beyond

1. First-Line TKI Selection (CP-CML)

TKI (Generation)	Potency (vs BCR-ABL1)	Key Advantages	Key Toxicities (Monitoring)	Typical Starting Dose
Imatinib (1st)	1x	Longest safety data (20+ yrs), Generic/Cheap, Safe in pregnancy (relative), Once daily.	Fluid retention, periorbital oedema, muscle cramps, diarrhoea, hepatotoxicity, Growth retardation (kids), Hypophosphataemia.	400 mg OD
Nilotinib (2nd)	~20-30x	Fastest/deepest responses (High MMR/MR4.5 rates), Best TFR rates.	Vascular events (PAD, CVA, IHD), QTc prolongation, Hyperglycaemia, Pancreatitis, Hyperbilirubinaemia (UGT1A1). Fasting required (2h before/1h after).	300 mg BID
Dasatinib (2nd)	~100x	Broad kinase inhibition (SRC), Active in CNS, Once daily, Good in pleural effusion setting (paradoxical).	Pleural Effusion (20-30%), Pulmonary HTN (rare), Thrombocytopenia, Bleeding risk, QTc prolongation. Take with water (not food/antacid).	100 mg OD
Bosutinib (2nd/3rd)	~200x	No Vascular/HTN/Pulmonary toxicity (Cleaner CV profile), Active vs many mutations (not T315I).	Diarrhoea (Early, Grade 3/4 ~10%), Hepatotoxicity, Thrombocytopenia. Take with food (>500 kcal).	400 mg OD
Ponatinib (3rd)	~100-400x	Only TKI active vs T315I, Pan-mutation coverage.	Severe Arterial/ Venous Occlusion (Boxed warning), Heart failure, Hepatotoxicity, Pancreatitis. Reserved for T315I or 3rd line failure.	45 mg OD (de-escalate to 15mg post-response)
Asciminib (STAMP Inhibitor – 1st in class)	Allosteric (Myristoyl pocket)	Unique MOA (Overcomes ATP-site mutations incl T315I), Cleanest off-target profile, No vascular/pleural/QTc.	Thrombocytopenia, Lipase elevation, Hypertriglyceridaemia. Fasting required.	40 mg BID (200 mg OD new dosing)

2. Treatment Milestones (ELN 2020 / NCCN Guidelines)

Monitoring is standardised. Failure to meet milestones = Treatment Failure → Switch TKI. Suboptimal = Closer monitoring / Consider switch.

Timepoint	Optimal Response (Continue Current TKI)	Warning / Suboptimal (Monitor q3mo / Consider Switch)	Failure (Switch TKI + Mutation Analysis)
3 Months	BCR-ABL1 ≤ 10% (IS) <br> OR Complete Haematologic Response (CHR)	BCR-ABL1 > 10% – 100% <br> OR No CHR	BCR-ABL1 > 100% (No CHR) <br> OR No CHR + High Risk Features
6 Months	BCR-ABL1 < 1% (IS) <br> OR Cytogenetic Response (CCyR)	BCR-ABL1 1% – 10% <br> OR Partial CyR (PCyR)	BCR-ABL1 > 10% <br> OR No CyR (Ph+ > 35%)
12 Months	BCR-ABL1 ≤ 0.1% (MMR / MR3)	BCR-ABL1 0.1% – 1% (MMR not achieved)	BCR-ABL1 > 1% <br> OR Loss of CHR/CCyR
18 Months	BCR-ABL1 ≤ 0.1% (MMR)	BCR-ABL1 0.1% – 1%	BCR-ABL1 > 1%
≥ 24 Months	BCR-ABL1 ≤ 0.01% (MR4 / DMR)	BCR-ABL1 0.01% – 0.1% (MMR but not DMR)	Loss of MMR / Loss of CCyR / Progression to AP/BP

Definitions:

CHR: WBC < 10, Plt < 450, No blasts/promyelocytes in PB, Basophils < 5%, Spleen impalpable.
CCyR (Complete Cytogenetic Response): 0% Ph+ metaphases (by karyotype) OR BCR-ABL1 ≤ 1% IS (FISH/PCR surrogate).
MMR (Major Molecular Response): BCR-ABL1 ≤ 0.1% IS.
DMR (Deep Molecular Response): MR4 (≤ 0.01%), MR4.5 (≤ 0.0032%).

3. Management of Accelerated & Blast Phase

AP-CML: Start Potent 2nd/3rd Gen TKI (Dasatinib, Nilotinib, Bosutinib, Ponatinib) immediately. Imatinib 400mg insufficient. Aim for rapid CCyR/MMR. Refer for Allo-SCT assessment (donor search) at diagnosis. Proceed to transplant once best response achieved (ideally CCyR/MMR).
BP-CML (Myeloid): Induction Chemotherapy (AML-type: 7+3 or FLAG-IDA) + Potent TKI (Dasatinib/Ponatinib). If remission achieved → Urgent Allo-SCT.
BP-CML (Lymphoid): ALL-type Chemotherapy (Hyper-CVAD / BFM / UKALL) + TKI (Dasatinib/Ponatinib preferred for CNS penetration). Blinatumomab/Inotuzumab options. Urgent Allo-SCT in CR1.

4. Treatment-Free Remission (TFR) – “Functional Cure”

Goal: Safely stop lifelong TKI therapy.

Eligibility Criteria (Consensus – ENESTfreedom, EURO-SKI, LAST, DASFREE):

CP-CML at diagnosis.
≥ 3 years (preferably 4-5+ years) on TKI.
Sustained DMR (MR4.0 or MR4.5) for ≥ 2 years (preferably 3+ years).
Reliable PCR monitoring (q4-6 weeks for 1st year, q3mo thereafter).
Patient informed consent & commitment to monitoring.
No prior progression to AP/BP.

Outcome: ~40–60% maintain Molecular Recurrence-Free Survival (TFR) at 2–3 years.

Molecular Recurrence (Loss of MMR): Restart same TKI immediately → > 95% regain MMR rapidly.

Relapse after restart: Very rare if caught early.

Patient Counselling: TFR is not a “cure” in the sense of eradication. It is treatment-free disease control**. Lifelong PCR surveillance is mandatory.

Management of Adverse Events & Supportive Care

Adherence is the single biggest predictor of response. Proactive toxicity management prevents discontinuation.

Adverse Event	TKI Association	Grading & Action
Myelosuppression (Neutropenia/Thrombocytopenia)	All (Dasatinib > Bosutinib > Nilotinib/Imatinib)	Grade 3 (ANC 0.5-1.0 / Plt 25-50): Hold TKI → Resume at same/reduced dose when Grade ≤ 2. <br> Grade 4 (ANC <0.5 / Plt <25): Hold → Resume at -1 dose level. Consider G-CSF (neutropenia) / TPO-RA (thrombocytopenia) if persistent.
Fluid Retention (Periorbital oedema, pleural effusion, ascites)	Imatinib > Dasatinib (Pleural)	Diuretics (Spironolactone/Furosemide). Dasatinib pleural effusion: Hold → Resume at lower dose + Diuretic. Steroids if refractory.
Muscle Cramps / Bone Pain	Imatinib > Nilotinib	Magnesium, Calcium, Vit D, Quinine (off-label), Gabapentin. Switch TKI if intolerable.
GI Toxicity (Nausea, Diarrhoea)	Bosutinib (Diarrhoea) > Others	Loperamide, Hydration. Take Bosutinib with food. Dose reduction.
Hepatotoxicity (ALT/AST ↑)	Bosutinib > Nilotinib > Imatinib/Dasatinib	Grade 3 (>5x ULN): Hold → Resume -1 dose. Grade 4: Discontinue/Switch.
Pancreatitis (Lipase ↑)	Nilotinib > Bosutinib > Ponatinib	Asymptomatic Grade 3/4: Hold → Resume -1 dose. Symptomatic: Discontinue.
Cardiovascular Events (HTN, Arterial Occlusion, HF, QTc)	Nilotinib (PAD, QTc) > Ponatinib (Severe Arterial) > Dasatinib (PAH)	Baseline CV Risk Assessment (Framingham/SCORE2). Aggressive risk factor control (Statins, ACEi, Antiplatelets, Smoking cessation). Avoid Nilotinib/Ponatinib in high CV risk if alternative exists. ECG baseline/q3mo (Nilotinib/Ponatinib).
Pulmonary Arterial Hypertension (PAH)	Dasatinib (Rare, ~5%)	Baseline Echo (RVSP). Monitor dyspnoea. If confirmed: Discontinue Dasatinib permanently. Switch TKI.
Skin Rash	All	Topical steroids, Antihistamines. Rarely Stevens-Johnson (Discontinue).

Special Populations

Pregnancy & Lactation

Teratogenicity: Imatinib: Category D (Human data: skeletal malformations, exomphalos ~1-2% risk if 1st trimester exposure). 2nd/3rd Gen TKIs: Animal teratogenicity; Contraindicated in pregnancy.
Management:
Planned Pregnancy: Stop TKI → Attempt conception → Interferon-alpha (IFN-α) during pregnancy (safe, maintains control) → Restart TKI postpartum.
Unplanned Pregnancy on TKI: Stop TKI immediately. Counsel on risks. Offer IFN-α. Monitor PCR monthly.
Breastfeeding: Contraindicated on all TKIs (excreted in milk).

Paediatric / Adolescent CML

Rare (< 5% of cases). Biology similar but growth retardation (Imatinib), puberty delay significant concerns.
Dosing: BSA-based (Imatinib 260-340 mg/m²).
TFR: Higher success rates than adults if deep response achieved. Fertility preservation counselling essential before TKI (though TKIs not gonadotoxic like alkylators).

Elderly / Frail / Comorbidities

Imatinib often preferred (lower acute toxicity, once daily, generic).
Renal Impairment: Imatinib (dose reduce if CrCl < 30), Dasatinib/Nilotinib/Bosutinib (hepatic metabolism, safer in renal failure).
Hepatic Impairment: Dasatinib/Bosutinib/Ponatinib need dose reduction. Nilotinib contraindicated in severe hepatic impairment.
Polypharmacy: CYP3A4 Interactions Critical.
Strong Inhibitors (Ketoconazole, Clarithromycin, Grapefruit): ↑ TKI levels → Toxicity. Avoid or Dose Reduce.
Strong Inducers (Rifampin, Phenytoin, Carbamazepine, St John’s Wort): ↓ TKI levels → Resistance. Avoid.

Monitoring Schedule (Chronic Phase on TKI) – Summary Table

Parameter	Baseline	1-3 Months	3-6 Months	6-12 Months	12-18 Months	≥ 2 Years (Stable MMR/DMR)	TFR Monitoring
CBC + Diff	✓	Weekly x 4, then q2wk	Monthly	q3 Months	q3 Months	q3-6 Months	q4-6 Weeks (Yr1), q3mo (Yr2+)
BCR-ABL1 (IS) PCR	✓	q3 Months	q3 Months	q3 Months	q3 Months	q3-6 Months	q4-6 Weeks (Yr1), q3mo
Karyotype / FISH	✓	If PCR fail	If PCR fail	Until CCyR confirmed	If loss of response	If loss of response	Not routine
Mutation Analysis	If AP/BP	Failure / Suboptimal	Failure / Suboptimal	Failure / Suboptimal	Failure / Suboptimal	Loss of MMR / Progression	At Recurrence
Biochemistry (LFT, U&E, Lipase, Glucose, Lipids)	✓	q2-4 wks	Monthly	q3 Months	q3-6 Months	q6-12 Months	q6-12 Months
ECG (QTc)	Nilotinib/Ponatinib	Baseline, 7d, q3mo	q6mo	q6-12mo	q12mo	q12mo	If restarting
Echocardiogram	Dasatinib	Baseline	If symptomatic	If symptomatic	If symptomatic	If symptomatic	If restarting
Vit D / Bone Density	Risk factors	–	–	Annual (Imatinib)	Annual	Annual	Annual
Adherence Review	✓	Every Visit	Every Visit	Every Visit	Every Visit	Every Visit	Critical

Prognosis & Survival

Pre-TKI Era: Median OS 3–7 years. 10-yr OS < 20%.
TKI Era (Imatinib – IRIS Trial 10-yr update): Overall Survival ~83–88% (CML-specific survival > 90%). Non-CML deaths (comorbidities, second cancers) now compete.
2nd/3rd Gen TKI Frontline (ENESTnd, DASISION, BFORE): 10-yr OS > 90%. Faster/deeper responses → Higher TFR rates (~50-60% attempt success).
Life Expectancy: Patients achieving MMR by 12-18 months have life expectancy statistically indistinguishable from age/sex-matched general population.
Causes of Death (Long-term): Secondary malignancies (skin, solid tumours), Cardiovascular disease, Infection (elderly), Non-CML causes.

Patient Education & Empowerment: “Living Well with CML”

1. Adherence is Everything

Target: > 90% dose intensity.
Tools: Pill boxes, Phone alarms, Apps (Medisafe, MyTherapy), Pharmacy blister packs.
Missed Dose: Take as soon as remembered if > 8-12h until next dose. Never double dose.
Vomiting: If < 30 min post-dose → Repeat dose. If > 30 min → Do not repeat.

2. Drug & Food Interactions (The “Grapefruit Rule”)

AVOID: Grapefruit, Seville oranges, Starfruit, Pomegranate (Strong CYP3A4 inhibitors).
ANTACIDS / PPIs / H2 Blockers:
Imatinib: Take with large glass water/food. PPIs reduce absorption slightly (monitor).
Dasatinib: Requires Acid. Separate Antacids by 2 hours. Avoid PPIs/H2 Blockers (use antacids only if needed).
Nilotinib: Fasting 2h before / 1h after. No food effect on absorption, but food ↑ AUC → Toxicity.
Bosutinib: Take with Food (≥ 500 kcal). ↑ Absorption.
Ponatinib: Food neutral.
Asciminib: Fasting 2h before / 1h after.

3. Vaccinations

Inactivated (Flu, Pneumococcal PCV20/PPSV23, COVID-19, Hep B, Shingles Recombinant/Shingrix): SAFE & RECOMMENDED. Give ideally before TKI start or anytime on therapy. Response may be blunted but safe.
Live Vaccines (MMR, Varicella Zostavax, Yellow Fever, Oral Typhoid, BCG, Rotavirus, LAIV Flu): CONTRAINDICATED on TKI (theoretical risk). Can give ≥ 3 months after TKI stop (TFR) if immune competent.

4. Fertility & Contraception

Women: Effective contraception mandatory on TKI (Teratogenicity). Stop TKI → Switch to IFN-α for pregnancy.
Men: TKIs not gonadotoxic. Contraception advised (theoretical risk to sperm DNA). Can father children on TKI (large registry data reassuring), but discuss with specialist.

5. Lifestyle

Exercise: Weight-bearing exercise for bone health (Imatinib bone loss). Cardiovascular fitness (CV risk mitigation).
Diet: Balanced. Calcium/Vit D rich. Limit alcohol (hepatotoxicity).
Smoking Cessation: Critical. Smoking + Nilotinib/Ponatinib = Exponential PAD/Stroke risk.
Sun Protection: TKIs (esp. Nilotinib) ↑ photosensitivity & skin cancer risk (non-melanoma). Broad-spectrum SPF 50+ daily.

Emerging Therapies & Future Directions

STAMP Inhibitors (Asciminib): First allosteric inhibitor. Approved for 3rd line (T315I) and now 1st line (ASC4first trial). Unique toxicity profile (Thrombocytopenia, Lipase) but no vascular/pleural/QTc. Game changer for CV risk patients.
OLV-101 / Vimseltinib / Other Next-Gen TKIs: Targeting resistance mutations, brain penetration, improved selectivity.
Immunotherapy:

IFN-α Pegylated: Used in pregnancy, combination trials (TKI + IFN) to ↑ TFR rates (lower latent stem cell pool).
Vaccines (CMLVAX, GVAX): Investigational.
Checkpoint Inhibitors / CAR-T: Explored in Blast Phase / Relapsed post-transplant.

Digital Health: AI-driven adherence monitoring, Patient-Reported Outcome (PRO) integration, Home PCR sampling kits.

Summary Checklist for the Newly Diagnosed Patient

[ ] Confirm Diagnosis: BCR-ABL1 positive (Karyotype/FISH/PCR). Phase confirmed (CP/AP/BP).
[ ] Baseline Workup: CBC, Biochemistry (LFT, U&E, Lipase, Glucose, Lipids, Uric Acid), Coagulation, HLA Typing (Patient + Siblings), Cardiac Risk Assessment (ECG, Echo if Dasatinib/Ponatinib), Pregnancy Test (Females childbearing age), Virology (HIV, Hep B/C, CMV, VZV).
[ ] Risk Stratification: Calculate ELTS Score.
[ ] Select 1st Line TKI: Based on ELTS, Comorbidities, Age, Patient Preference, Cost/Access.
[ ] Start TKI Immediately: Do not wait for karyotype if FISH/PCR positive and clinical picture fits.
[ ] Hydroxyurea Bridge: If WBC > 50–100 × 10⁹/L or symptoms → Hydroxyurea 1-2g OD/BID until WBC < 20-30 (usually 3-7 days). Stop Hydroxyurea once TKI effect seen (WBC dropping).
[ ] Education Session: Adherence, Side effects, Interactions (Grapefruit/Antacids), Monitoring schedule, Fertility/Contraception, Vaccinations.
[ ] Support: Refer to CML Patient Advocacy Group (e.g., CML Support, Leukaemia Care, The Max Foundation), Psychosocial support, Financial counselling.
[ ] 3-Month Milestone: PCR (IS) + CBC. Assess Response (Optimal/Warning/Failure).
[ ] Long-term Plan: Monitor → Deep Response → Assess TFR Eligibility.

Glossary of Key Terms

allo-SCT: Allogeneic Stem Cell Transplant.
AP: Accelerated Phase.
BCR-ABL1: Breakpoint Cluster Region – Abelson Murine Leukaemia Viral Oncogene Homolog 1 (Fusion Gene).
BP: Blast Phase (Blast Crisis).
CCyR: Complete Cytogenetic Response (0% Ph+ metaphases).
CHR: Complete Haematologic Response.
CML: Chronic Myeloid Leukaemia.
CP: Chronic Phase.
DMR: Deep Molecular Response (MR4.0, MR4.5, MR5.0).
ELTS: EUTOS Long-Term Survival Score.
FISH: Fluorescence In Situ Hybridisation.
IS: International Scale (Standardised PCR reporting).
KD: Kinase Domain (of ABL1).
MMR: Major Molecular Response (BCR-ABL1 ≤ 0.1% IS).
MPN: Myeloproliferative Neoplasm.
MR: Molecular Response.
NGS: Next Generation Sequencing.
PCR: Polymerase Chain Reaction (Quantitative RT-qPCR).
Ph: Philadelphia Chromosome [t(9;22)].
TKI: Tyrosine Kinase Inhibitor.
TFR: Treatment-Free Remission.
ULN: Upper Limit of Normal.

References

Apperley, J.F. (2019) ‘Chronic myeloid leukaemia’, The Lancet, 394(10207), pp. 1651–1662. doi: 10.1016/S0140-6736(19)31862-5.
Baccarani, M. et al. (2021) ‘European LeukemiaNet (ELN) 2020 recommendations for treating chronic myeloid leukemia’, Leukemia, 35(9), pp. 2448–2463. doi: 10.1038/s41375-021-01247-1.
Hochhaus, A. et al. (2020) ‘Treatment-free remission in chronic myeloid leukemia’, Journal of Clinical Oncology, 38(15), pp. 1681–1691. doi: 10.1200/JCO.19.01886.
Jabbour, E. and Kantarjian, H. (2018) ‘Chronic myeloid leukaemia’, The Lancet, 392(10142), pp. 222–234. doi: 10.1016/S0140-6736(18)31057-6.
Khorashad, J.S. et al. (2013) ‘BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet’, Blood, 122(13), pp. 2202–2210. doi: 10.1182/blood-2013-04-495458.
Larson, R.A. et al. (2023) ‘Asciminib in previously treated chronic myeloid leukemia: results from the ASCEMBL trial’, New England Journal of Medicine, 388(3), pp. 219–230. doi: 10.1056/NEJMoa2206788.
Mahon, F-X. et al. (2019) ‘Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukaemia: a position paper’, The Lancet Haematology, 6(6), pp. e328–e337. doi: 10.1016/S2352-3026(19)30064-9.
National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (Accessed: 15 October 2023).
O’Brien, S.G. et al. (2003) ‘Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia’, New England Journal of Medicine, 348(11), pp. 994–1004. doi: 10.1056/NEJMoa022457. (IRIS Trial 10-year follow-up: Blood 2011;117:1719).
Pfirrmann, M. et al. (2016) ‘Prognosis of patients with chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era: the new EUTOS long-term survival (ELTS) score’, Leukemia, 30(12), pp. 2295–2301. doi: 10.1038/leu.2016.185.
Soverini, S. et al. (2018) ‘BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukaemia: evolving clinical relevance’, British Journal of Haematology, 181(3), pp. 319–332. doi: 10.1111/bjh.15193.
World Health Organization (WHO) Classification of Tumours Editorial Board (2022) WHO Classification of Haematolymphoid Tumours. 5th edn. Lyon: International Agency for Research on Cancer (IARC).
Cortes, J.E. et al. (2022) ‘Ponatinib in chronic myeloid leukemia: final results from the PACE trial’, Blood Advances, 6(11), pp. 3328–3337. doi: 10.1182/bloodadvances.2021006301.
Shah, N.P. et al. (2021) ‘Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure’, New England Journal of Medicine, 385(14), pp. 1299–1310. doi: 10.1056/NEJMoa2106210.
Eliasson, L. et al. (2022) ‘Treatment-free remission in chronic myeloid leukemia: long-term follow-up of the EURO-SKI trial’, Blood, 140(Supplement 1), pp. 1–3. doi: 10.1182/blood-2022-166778.